Cargando…

The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs

Introduction: Clinical trials are the gold standard for testing new therapies. Databases like ClinicalTrials.gov provide access to trial information, mainly covering the US and Europe. In 2006, WHO introduced the global ICTRP, aggregating data from ClinicalTrials.gov and 17 other national registers,...

Descripción completa

Detalles Bibliográficos
Autores principales: Namiot, Eugenia D., Smirnovová, Diana, Sokolov, Aleksandr V., Chubarev, Vladimir N., Tarasov, Vadim V., Schiöth, Helgi B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544909/
https://www.ncbi.nlm.nih.gov/pubmed/37790806
http://dx.doi.org/10.3389/fphar.2023.1228148
_version_ 1785114570841391104
author Namiot, Eugenia D.
Smirnovová, Diana
Sokolov, Aleksandr V.
Chubarev, Vladimir N.
Tarasov, Vadim V.
Schiöth, Helgi B.
author_facet Namiot, Eugenia D.
Smirnovová, Diana
Sokolov, Aleksandr V.
Chubarev, Vladimir N.
Tarasov, Vadim V.
Schiöth, Helgi B.
author_sort Namiot, Eugenia D.
collection PubMed
description Introduction: Clinical trials are the gold standard for testing new therapies. Databases like ClinicalTrials.gov provide access to trial information, mainly covering the US and Europe. In 2006, WHO introduced the global ICTRP, aggregating data from ClinicalTrials.gov and 17 other national registers, making it the largest clinical trial platform by June 2019. This study conducts a comprehensive global analysis of the ICTRP database and provides framework for large-scale data analysis, data preparation, curation, and filtering. Materials and methods: The trends in 689,793 records from the ICTRP database (covering trials registered from 1990 to 2020) were analyzed. Records were adjusted for duplicates and mapping of agents to drug classes was performed. Several databases, including DrugBank, MESH, and the NIH Drug Information Portal were used to investigate trends in agent classes. Results: Our novel approach unveiled that 0.5% of the trials we identified were hidden duplicates, primarily originating from the EUCTR database, which accounted for 82.9% of these duplicates. However, the overall number of hidden duplicates within the ICTRP seems to be decreasing. In total, 689 793 trials (478 345 interventional) were registered in the ICTRP between 1990 and 2020, surpassing the count of trials in ClinicalTrials.gov (362 500 trials by the end of 2020). We identified 4 865 unique agents in trials with DrugBank, whereas 2 633 agents were identified with NIH Drug Information Portal data. After the ClinicalTrials.gov, EUCTR had the most trials in the ICTRP, followed by CTRI, IRCT, CHiCTR, and ISRCTN. CHiCTR displayed a significant surge in trial registration around 2015, while CTRI experienced rapid growth starting in 2016. Conclusion: This study highlights both the strengths and weaknesses of using the ICTRP as a data source for analyzing trends in clinical trials, and emphasizes the value of utilizing multiple registries for a comprehensive analysis.
format Online
Article
Text
id pubmed-10544909
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105449092023-10-03 The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs Namiot, Eugenia D. Smirnovová, Diana Sokolov, Aleksandr V. Chubarev, Vladimir N. Tarasov, Vadim V. Schiöth, Helgi B. Front Pharmacol Pharmacology Introduction: Clinical trials are the gold standard for testing new therapies. Databases like ClinicalTrials.gov provide access to trial information, mainly covering the US and Europe. In 2006, WHO introduced the global ICTRP, aggregating data from ClinicalTrials.gov and 17 other national registers, making it the largest clinical trial platform by June 2019. This study conducts a comprehensive global analysis of the ICTRP database and provides framework for large-scale data analysis, data preparation, curation, and filtering. Materials and methods: The trends in 689,793 records from the ICTRP database (covering trials registered from 1990 to 2020) were analyzed. Records were adjusted for duplicates and mapping of agents to drug classes was performed. Several databases, including DrugBank, MESH, and the NIH Drug Information Portal were used to investigate trends in agent classes. Results: Our novel approach unveiled that 0.5% of the trials we identified were hidden duplicates, primarily originating from the EUCTR database, which accounted for 82.9% of these duplicates. However, the overall number of hidden duplicates within the ICTRP seems to be decreasing. In total, 689 793 trials (478 345 interventional) were registered in the ICTRP between 1990 and 2020, surpassing the count of trials in ClinicalTrials.gov (362 500 trials by the end of 2020). We identified 4 865 unique agents in trials with DrugBank, whereas 2 633 agents were identified with NIH Drug Information Portal data. After the ClinicalTrials.gov, EUCTR had the most trials in the ICTRP, followed by CTRI, IRCT, CHiCTR, and ISRCTN. CHiCTR displayed a significant surge in trial registration around 2015, while CTRI experienced rapid growth starting in 2016. Conclusion: This study highlights both the strengths and weaknesses of using the ICTRP as a data source for analyzing trends in clinical trials, and emphasizes the value of utilizing multiple registries for a comprehensive analysis. Frontiers Media S.A. 2023-09-18 /pmc/articles/PMC10544909/ /pubmed/37790806 http://dx.doi.org/10.3389/fphar.2023.1228148 Text en Copyright © 2023 Namiot, Smirnovová, Sokolov, Chubarev, Tarasov and Schiöth. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Namiot, Eugenia D.
Smirnovová, Diana
Sokolov, Aleksandr V.
Chubarev, Vladimir N.
Tarasov, Vadim V.
Schiöth, Helgi B.
The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs
title The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs
title_full The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs
title_fullStr The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs
title_full_unstemmed The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs
title_short The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs
title_sort international clinical trials registry platform (ictrp): data integrity and the trends in clinical trials, diseases, and drugs
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544909/
https://www.ncbi.nlm.nih.gov/pubmed/37790806
http://dx.doi.org/10.3389/fphar.2023.1228148
work_keys_str_mv AT namioteugeniad theinternationalclinicaltrialsregistryplatformictrpdataintegrityandthetrendsinclinicaltrialsdiseasesanddrugs
AT smirnovovadiana theinternationalclinicaltrialsregistryplatformictrpdataintegrityandthetrendsinclinicaltrialsdiseasesanddrugs
AT sokolovaleksandrv theinternationalclinicaltrialsregistryplatformictrpdataintegrityandthetrendsinclinicaltrialsdiseasesanddrugs
AT chubarevvladimirn theinternationalclinicaltrialsregistryplatformictrpdataintegrityandthetrendsinclinicaltrialsdiseasesanddrugs
AT tarasovvadimv theinternationalclinicaltrialsregistryplatformictrpdataintegrityandthetrendsinclinicaltrialsdiseasesanddrugs
AT schiothhelgib theinternationalclinicaltrialsregistryplatformictrpdataintegrityandthetrendsinclinicaltrialsdiseasesanddrugs
AT namioteugeniad internationalclinicaltrialsregistryplatformictrpdataintegrityandthetrendsinclinicaltrialsdiseasesanddrugs
AT smirnovovadiana internationalclinicaltrialsregistryplatformictrpdataintegrityandthetrendsinclinicaltrialsdiseasesanddrugs
AT sokolovaleksandrv internationalclinicaltrialsregistryplatformictrpdataintegrityandthetrendsinclinicaltrialsdiseasesanddrugs
AT chubarevvladimirn internationalclinicaltrialsregistryplatformictrpdataintegrityandthetrendsinclinicaltrialsdiseasesanddrugs
AT tarasovvadimv internationalclinicaltrialsregistryplatformictrpdataintegrityandthetrendsinclinicaltrialsdiseasesanddrugs
AT schiothhelgib internationalclinicaltrialsregistryplatformictrpdataintegrityandthetrendsinclinicaltrialsdiseasesanddrugs